PT  - JOURNAL ARTICLE
AU  - Jefferson, T
AU  - Jones, MA
AU  - Al-Ansary, L
AU  - Bawazeer, GA
AU  - Beller, EM
AU  - Clark, J
AU  - Conly, JM
AU  - Del Mar, C
AU  - Dooley, E
AU  - Ferroni, E
AU  - Glasziou, P
AU  - Hoffmann, T
AU  - Thorning, S
AU  - van Driel, ML
TI  - Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 - Face masks, eye protection and person distancing: systematic review and meta-analysis
AID  - 10.1101/2020.03.30.20047217
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.30.20047217
4099  - http://medrxiv.org/content/early/2020/03/30/2020.03.30.20047217.short
4100  - http://medrxiv.org/content/early/2020/03/30/2020.03.30.20047217.full
AB  - OBJECTIVE To examine the effectiveness of eye protection, face masks, or person distancing on interrupting or reducing the spread of respiratory viruses.DESIGN Update of a systematic review and meta-analysis.DATA SOURCES Eligible trials from the previous review; search of Cochrane Central Register of Controlled Trials, PubMed, Embase and CINAHL from October 2010 up to 9 March 2020; and forward and backward citation analysis.DATA SELECTION Randomised and cluster-randomised trials of people of any age, testing the use of eye protection, face masks, or person distancing against standard practice, or a similar physical barrier. Outcomes included any acute respiratory illness and its related consequences.DATA EXTRACTION AND ANALYSIS Six authors independently, in pairs, assessed risk of bias and extracted data. We used a generalised inverse variance method for pooling using a random effects model and reported results with risk ratios and 95% Confidence Intervals (CI). We assessed risk of bias using the Cochrane tool.RESULTS We included 15 (cluster) randomised trials investigating the effect of masks (14 trials) in healthcare workers and general population and of quarantine (1 trial). We found no trials testing eye protection. There was no reduction of influenza-like illness (ILI) cases (Risk Ratio 0.93, 95%CI 0.83 to 1.05) or laboratory-confirmed influenza (Risk Ratio 0.84, 95%CI 0.61-1.17) for masks compared to no masks in the general population, nor in healthcare workers (Risk Ratio 0.37, 95%CI 0.05 to 2.50). There was no difference between surgical masks and N95 respirators: for ILI Risk Ratio 0.83 (95%CI 0.63 to 1.08), for laboratory-confirmed influenza Risk Ratio 1.02 (95%CI 0.73 to 1.43). Harms was poorly reported and limited to discomfort resulting in lower compliance with wearing. The only trial testing quarantining workers with household ILI contacts found a reduction in ILI cases at work, but an increased risk of quarantined workers to contract influenza.CONCLUSIONS Despite the poor quality of design and reporting of most trials, we would still recommend healthcare workers use facial barriers. We found no evidence of a difference between surgical masks and N95 respirators. There is only limited evidence to support effectiveness of quarantine. Based on observational evidence from the previous SARS epidemic, large trials comparing full facial protection with surgical masks need to be carried out. Funding for such trials is critical to adequately inform policy and global pandemic preparedness.Competing Interest StatementTom Jefferson (TJ) was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018). In 2014-2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current). TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16) TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017). TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery. TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022). TJ consults for Illumina LLC on next generation gene sequencing (2019-). TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Servizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019). TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe (excluding devices relating to acute respiratory infections). John Conly holds grants from the Canadian Institutes for Health Research, Alberta Innovates-Health Solutions and was the primary local Investigator for a Staphylococcus aureus vaccine study funded by Pfizer for which all funding was provided only to the University of Calgary for the conduct of the trial. All other authors have no interests to declare.Funding StatementNIHR grant number NIHR130721Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in this review are from published journal articles. Extraction sheets are available from correspoding author. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006207.pub4/full